Navigation Links
Veto of California's Condoms in Prisons Bill: "Politics Over Public Health," Says AHF
Date:10/15/2007

ointed that Governor Schwarzenegger chose to veto AB 1334, a bill that would have helped reduce the spread of HIV and other STDs among California inmates and their post-incarceration partners," said Michael Weinstein, President of AIDS Healthcare Foundation. "While there will be benefits coming from the Governor's proposal to implement a pilot program in one state prison, there are still 32 other institutions in which inmates -- and subsequently their partners at home -- will be exposed to HIV unnecessarily. We cannot waste precious time creating pilot programs to prove the effectiveness of public health measures that have been effective for a quarter of a century. With his veto of AB 1334, we believe the Governor is sadly putting politics over public health."

Passed by state legislators in early September, the bill, would have allowed nonprofit and health agencies to provide condoms to inmates in state prisons, where HIV prevalence is 8 to 10 times greater than in the general population.

"Existing condom distribution programs in jails in New York, Philadelphia, Washington, DC, San Francisco and Los Angeles already demonstrate that this California law could have worked without threatening safety and security in the state's correctional facilities; they are the de facto pilot program," said Joseph Terrill, Public Policy Coordinator for AIDS Healthcare Foundation. "California's prison and public health officials often walk a fine line as they try to grapple with controlling the spread of HIV and other sexually transmitted diseases among inmates in the state's prison population while following state law. The availability and use of condoms -- a proven risk-reduction strategy -- would have improved inmates' individual health outcomes and helped reduce costs to the state's overburdened prison health care system. We thank Assembly Member Swanson for authoring and carrying AB 1334, but remain saddened by the Governor's veto of this potentially lifesaving bill
'/>"/>

SOURCE AIDS Healthcare Foundation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
6. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
7. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
8. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
9. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
10. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) ... secured $1 million in 12% per annum short term ... is an initial drawdown of $500,000, with accrued interest ... of $500,000 with accrued interest and principal repayable in ... Company becoming cashflow positive for any calendar month prior ...
(Date:12/16/2009)... December 16 Scientists at,deCODE genetics, Inc. ... the,discovery of a version of a common single-letter ... with a major impact on susceptibility to type ... is not only large, but unusual:,if an individual ... risk of,T2D by more than 30% compared to ...
(Date:12/16/2009)... Wis., Dec. 16 EuroPharma, Inc. ... for the use of super absorbency BCM-95® ... EuroPharma formulations. The exclusive distribution territory ... health food store channel and professional channel, ... and clinics. BCM-95® is a highly ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 2deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 3deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin 4EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 1Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 2Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 3Award recognizes 30 years of anti smoking work 59213 1Award recognizes 30 years of anti smoking work 59213 2Developing enzymes to clean up pollution by explosives 10312 1
... Results presented at the Movement Disorder Society's 11th,International ... 08, 2007 /PRNewswire-FirstCall/ -- New,information on the use ... disease (PD) was reported this week at The,Movement ... approved by the FDA May 17, 2006, for ...
... 8, 2007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today ... including efficacy, safety and improvements in,patient-centered ... (DPN) pain treated with the investigational ... and sigma-1 agonist. The data were ...
Other Medicine Technology:International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 2International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 3International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 4International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 5International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7
(Date:12/17/2009)... Children’s Hospital from nearby hot tub company helps raise money ... ... Salt Lake City, UT (PRWEB) December ... the donation of a Bullfrog Spa to aid in fund ... City, Utah. Primary Children’s Medical Center, serving child patients from ...
(Date:12/16/2009)... sector revenue increased by 5.7 percent in 2008 ... 2007, according to new data from the U.S. ... North American Industry Classification System as NAICS 62. ... come from the 2008 Service Annual Survey: ... of tables which provides estimates of revenue, sources ...
(Date:12/16/2009)... 16 Smart Balance, Inc. (Nasdaq: SMBL ... authorized a two-year stock repurchase program of up to ... program demonstrates the confidence we have in the prospects ... long-term value for all of our shareholders, while at ... Stephen Hughes, Smart Balance, Inc. Chairman and Chief Executive ...
(Date:12/16/2009)... CHASE, Md., Dec. 16 New Enterprise ... firm, today announced that one of its portfolio ... agreement to be acquired by Ethicon, Inc., a ... for approximately $785 million (net of estimated cash ... technology company dedicated to designing, developing and commercializing ...
(Date:12/16/2009)... gain full benefit from breakthroughs, experts say, , , WEDNESDAY, ... lines currently used for research come mostly from white ... mean that non-whites will benefit less from any medical ... experts say. , Blacks could be especially affected. In ... lines studied showed any traces of recent African ancestry, ...
Breaking Medicine News(10 mins):Health News:Bullfrog Spas Helps Critically Ill Children 2Health News:Bullfrog Spas Helps Critically Ill Children 3Health News:Bullfrog Spas Helps Critically Ill Children 4Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 2Health News:Census Bureau: Health Care Industries Showed Modest Growth in Revenue in 2008 3Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Most Stem Cells Used in Research Come From Whites 2
... of Texas, 181,legislators are being honored with the ... accomplishments on behalf of health care,during the 80th ... created the award in 1997 to honor state ... on issues important,to hospitals and health systems. ...
... WASHINGTON, Oct. 15 Arthur H. Rubenstein,MBBCh, executive vice ... medicine, and Robert G. Dunlop professor of medicine at ... board of directors of the,Association of Academic Health Centers., ... School of Medicine in New,York before assuming his current ...
... pose big stomach risks, study notes , , MONDAY, ... don,t tell their doctors that they take common over-the-counter ... omission, a new study has found. , "With nearly ... it is no wonder that adverse events are increasing ...
... PA and VANCOUVER, BC, Oct. 15 /PRNewswire/ - ... pain drugs, announced today it has successfully reached ... (FDA) under the,Special Protocol Assessment (SPA) process for ... (OROS(R) Hydromorphone) for the treatment of,chronic pain. A ...
... Calif., Oct. 15 Edwards Lifesciences,Corporation (NYSE: EW ... advanced cardiovascular disease, plans to announce its operating,results for ... closes on,Monday, October 22, 2007 and will host a ... its results. To participate in the conference call, ...
... by gift from P&G, PHILADELPHIA, Oct. 15 ... for Clinical Research & Education,today announced a commitment ... gift to the ACG Institute,s Capital Campaign boosts ... in more than $16 million to,support clinical research, ...
Other Medicine News:Health News:THA Honors Nine Legislators for Contributions to Health Care 2Health News:Association of Academic Health Centers Names University of Pennsylvania's Dr. Arthur H. Rubenstein Chairman of the Board of Directors 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 2Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 3Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2Health News:ACG Announces Generous Gift by Procter & Gamble 2
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Available in 5, 8 and 12 mm bite, with and without teeth....
...
...
Medicine Products: